Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
914 PLN | +1.11% | +1.44% | -1.19% |
Mar. 23 | NEUCA S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | NEUCA S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.33 for the 2024 fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.19% | 998M | B- | ||
+16.09% | 71.39B | C+ | ||
+2.01% | 25.1B | C+ | ||
-1.22% | 8.59B | C | ||
+7.95% | 8.19B | B | ||
-20.48% | 7.91B | B- | ||
+15.26% | 4.31B | B+ | ||
-1.24% | 3.93B | B- | ||
-3.02% | 3.86B | B | ||
+21.10% | 3.64B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NEU Stock
- Ratings NEUCA S.A.